Combination CCNU and vinblastine chemotherapy for canine mast cell tumours: 57 cases.
The purpose of this study was to evaluate the efficacy and toxicity of a CCNU and vinblastine chemotherapy protocol for canine mast cell tumours. Fifty-seven tumours in 56 dogs were evaluated, 37 had macroscopic disease and 20 had microscopic disease. A 57% response rate was seen in dogs with macroscopic disease for a median duration of 52 weeks. Dogs with macroscopic disease had a median progression free survival time (PFST) of 30 weeks and a median overall survival time (OST) of 35 weeks. Dogs with microscopic disease had a median PFST of 35 weeks and a median OST of 48 weeks. Toxicity was recorded in 54% of the dogs treated, with the majority of events being mild. This chemotherapy protocol appears to be well tolerated and should be considered for canine mast cell tumours.
Cooper
Maureen
M
Melbourne Veterinary Specialist Centre, Glen Waverley, VIC, Australia. maureenacooper@hotmail.com
Tsai
Xinru
X
Bennett
Peter
P
D000818:Animals; D000971:Antineoplastic Combined Chemotherapy Protocols; D004283:Dog Diseases / Q000188:drug therapy*; D004285:Dogs; D005260:Female; D008130:Lomustine / Q000008:administration & dosage / Q000627:therapeutic use*; D008297:Male; D034801:Mastocytoma / Q000188:drug therapy / Q000662:veterinary*; D014747:Vinblastine / Q000008:administration & dosage / Q000627:therapeutic use*
D014747:Vinblastine; D008130:Lomustine